dc.contributor.author |
RABBIYA TAHIR, Supervised By Dr Nosheen Fatima |
|
dc.date.accessioned |
2020-10-28T12:52:27Z |
|
dc.date.available |
2020-10-28T12:52:27Z |
|
dc.date.issued |
2017 |
|
dc.identifier.uri |
http://10.250.8.41:8080/xmlui/handle/123456789/6751 |
|
dc.description.abstract |
Nanoparticles with a drug basis have emerged and caught attention in recent past because of its use in drug synthesis. Nanoparticles are reported for their role in enhancing bio-availability, reducing side effects in case of toxic drugs and extending the drug release. Diclofenac sodium (D.sod) is used for the treatment of inflammatory diseases. Excessive use of D.sod leads to severe side effects such as renal insuffiencecy and mucosal bleeding. This study was conducted to synthesize the pegylated diclofenac sodium gold nanoparticles (PEG-DAuNps). In-vitro anti-inflammatory activity is carried out using human red blood cell membrane (HRBC) stabilization method and egg albumin induced paw edema method is conducted for in-vivo anti-inflammatory analysis. DAuNps nanoparticles were prepared using chemical reduction method. The characterization of PEG-DAuNps was done by Fourier Transform Infrared Spectroscopy (FTIR) and Ultraviolet-Visible Spectroscopy. The average size of prepared nanoparticles is 26nm.In-vitro release study of PEG-DAuNps showed sustained drug release. PEG-DAuNps showed faster reduction in paw thickness of mice. PEG-DAuNps showed higher protection towards HRBC membrane. PEG-DAuNps could be used as a potential therapeutic agent for the treatment of inflammatory diseases with reduced side effects. |
en_US |
dc.language.iso |
en_US |
en_US |
dc.publisher |
SMME-NUST |
en_US |
dc.relation.ispartofseries |
SMME-TH-252; |
|
dc.subject |
Diclofenac sodium, Anti-inflammatory drug, Paw edema, Gold nanoparticles, Pegylation. |
en_US |
dc.title |
DRUG DELIVERY SYSTEM OF DICLOFENAC SODIUM AND ITS APPLICATIONS IN THE TREATMENT OF INFLAMMATION AND EDEMA |
en_US |
dc.type |
Thesis |
en_US |